Vimarsana
Biggest News Aggregation in the World

Page 2 - Roxana Mehran News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roxana Mehran. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roxana Mehran Today - Breaking & Trending Today

Beta-Blockers Fail to Deliver Secondary Prevention Benefit in Key MI Patients - Vimarsana News

Beta-Blockers Fail to Deliver Secondary Prevention Benefit in Key MI Patients

Standard medications losing appeal amid more modern heart attack treatments

New survey uncovers lack of awareness around heart valve disease and risk factors among women - Vimarsana News

New survey uncovers lack of awareness around heart valve disease and risk factors among women

Despite prevalence of chronic conditions associated with aortic stenosis in women over 65, the majority have never been referred to a cardiologist; Racial disparities may present further opportunities...

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment - Vimarsana News

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment

WHIPPANY, N.J.--(BUSINESS WIRE)--Nov 10, 2023--

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anti - Vimarsana News

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anti

New study includes patients aged ≥65 years with atrial fibrillation (AF) at high risk for ischemic stroke or systemic embolism who are deemed ineligible for oral anticoagulant (OAC) treatment due to increased risk of bleedingOCEANIC-AFINA, the latest Phase III study in the OCEANIC clinical trial program, will invest...

Guiding DAPT Based on Genes or Platelet Tests Still 'Tempting' - Vimarsana News

Guiding DAPT Based on Genes or Platelet Tests Still 'Tempting'

Taken together, a host of neutral or underpowered studies hint at a benefit to personalizing DAPT decisions, a new review argues.

Source: tctmd.com